That prostaglandin E (PGE) plays some part in rheumatoid arthritis (RA) has been suggested by several lines of observations. E type prostaglandin appears to stimulate bone resorption in RA joints. 1 The localisation and production of PGE in rheumatoid synovial tissues have been demonstrated by an immunohistochemical method2 and radioimmunoassay. 3 PGE has been detected in the joint fluids from RA patients, and the PG level in patients treated with nonsteroidal anti-inflammatory agents is lower than in untreated persons. & 6 However, these reports do not compare PGE levels in the same patients before and after treatment, except in one case described by Higgs et al. 4 Moreover, none of these reports deals with the correlation between drug-induced change of PGE level and extent of inflammatory response in the joint tissues.
The present study was undertaken in an attempt to study the changes of fluid volume, cell contents, and PGE level in the joint fluids from the same patients with RA and osteoarthritis (OA) after treatment Accepted for publication 6 1 Relation between prostaglandin E (PGE) and leucocyte count in the joint fluids of RA patients before and after the anti-inflammatory therapy with flurbiprofen.
The levels of PGE (ng/ml) were plotted against leucocyte count (cells/mm3). 1 2 ng/ml, while the levels of OA patients fell into a comparatively low and narrow range from 1I5 to 1 * 0 ng/ml.
During the anti-inflammatory therapy with flurbiprofen the PGE levels in RA patients with the initial PGE values higher than 3*2 ng/ml declined by 72-38%, while the remaining 4 cases with the initial PGE levels not higher than 1-4 ng/ml kept their initial levels in spite of the drug treatment (Fig. 1) .
The PGE in OA patients, whose PGE levels in the joint fluids were also at a low level, namely 1 -5-1-0 ng/ml, did not respond to the therapy at all.
No significant change was observed in respect of the cell counts or volume of the joint fluid after the therapy with flurbiprofen either in RA or in OA.
Discussion
Inflammation of articular tissue in OA appears to be due mainly to mechanical injury of the tissues caused by deformation of the joint structures, namely, bone, cartilage, and ligaments. On the other hand immune complexes are thought to play an important role in the pathogenesis of rheumatoid synovitis.
Effusion of joint fluids in these joint diseases is thought to be derived from inflammatory lesions of articular tissues. However, the exact mechanisms mediating vascular permeability in these diseases are not well understood yet. In a variety of clinical and experimental inflammations E type prostaglandin generated in injured tissues is considered to be of importance in the mediation of hyperalgesia, vasodilatation, increased vascular permeability, and fever. 13 In the present study, however, no apparent correlation was observed in RA between PGE levels in the joint fluid and various parameters generally accepted as indicators of severity of RA inflammation such as the ESR, serum CRP, and volume of the joint fluids aspirated from affected knee joints, apart from cell counts ( Table 1 , Fig. 1 ).
Data on PGB levels and leucocyte counts in joint fluids of rheumatic diseases presented by Robinson and Levine14 also include findings suggesting that there is no correlation between these 2 parameters. The inflammatory group designated by them on the basis of cell counts 1000/mm3 or more in the joint fluids showed extensive variation in PGB levels in the joint fluids, with very low values that could not be distinguished from those of the noninflammatory (<1000 cells/mm3) group.
In addition, our data on the influence of flurbiprofen to the joint fluids also appear to be inconsistent with the general concept of the role of PGE in inflammation. When the drug was administrated to RA patients with a high level of PGE in joint fluids (patients 1, 2, 3, and 4), the PGE levels decreased markedly without affecting either effusion ofjoint fluids or emigration of cells into the fluids (Table 1) . Moreover in half (4) the RA cases and all the 4 OA cases effusion of joint fluids took place in spite of a comparatively low level in PGE in the fluid, but in addition the PGE level and effusion of joint fluid were refractory to anti-inflammatory therapy with flurbiprofen.
Trang et al.6 report, though without including precise data, that all patients treated with various non-steroidal anti-inflammatory drugs still developed acute exudative arthritis in spite of treatment which led to much lower levels of PG's in joint fluid than in untreated patients. The present study, based on the observations made on same patients before and after anti-inflammatory treatment, has provided new evidence in favour of such concepts.
Recent novel studies by Samuelsson 15 have shown that the leucotriens are produced from arachnoidic acid by leucocytes through the lipoxygenase pathway. Leucotrien B has an extremely potent chemotactic Change ofprostaglandin Elevel in jointfluids after treatment withflurbiprofen 465 activity. 16 The lipoxygenase pathway is not affected by aspirin-like drugs such as flurbiprofen. The ineffectiveness of our therapy with flurbiprofen on cell counts may therefore be explained along these lines.
Ferreira'3 reported that prostaglandins do not cause overt pain but hyperalgesia; thus, they can sensitise pain receptors. Our clinical impression is that the arthralgia of RA is suppressed in varying degrees after anti-inflammatory therapy with nonsteroidal drugs. The significance of PG synthesis inhibitors in anti-inflammatory therapy might be evaluated on the basis of their analgesic effect. 
